Bukwang stops marketing of clevudine tentatively

Bukwang Pharm said it has voluntarily halted the marketing of Levovir (clevudine) for the treatment of chronic hepatitis B (HBV) infection as its US partner Pharmasset, Inc. decided to voluntarily terminate Phase III QUASH studies of clevudine on April 20.

Pharmasset recently became aware of a number of spontaneous Serious Adverse Event reports and Events of Special Interest in patients rece...